21Jun/24

Nature’s Breakthrough: ADCs and Base Editing Transform Blood Disease Treatment

June 21, 2024ReviewBlood Disease ADC, CD45-targeted Therapybioadc

Researchers from the University of Basel in Switzerland published a research paper titled “Selective haematological cancer eradication with preserved haematopoiesis” in the journal Nature. The entire hematopoietic system can be reconstructed byRead More…

14May/24

ADCs in Cancer Therapy: Innovations, Challenges, and Outlooks

May 14, 2024ReviewADC, ADC resistance, AJICAP technology, Cancer Therapybioadc

The emergence of antibody-drug conjugates (ADCs) as a potential cancer treatment pathway has attracted a great deal of attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drugRead More…

21Apr/24

It’s High Time For Next Generation Adcs To Set Out: 5 Ways To Go – Part II

April 21, 2024ReviewDAC, ISAC, PDCbioadc

Conditionally activated antibody prodrug conjugate (PDC) Traditional ADCs not only target receptors expressed on tumor cells but also those on certain healthy tissues, leading to inevitable off-tumor toxicity. Probody Drug Conjugates (PDCs)Read More…

19Apr/24

It’s High Time For Next Generation Adcs To Set Out: 5 Ways To Go

April 19, 2024ReviewADC design, Next Generation ADCbioadc

Antibody-drug conjugates (ADCs) represent a highly promising approach to cancer treatment, capable of selectively delivering highly cytotoxic payloads to tumors. However, ADCs are currently facing a series of challenges, including resistance, tumorRead More…

22Mar/24

Optimization Strategies for ADC and Related Bioanalytical Methods

March 22, 2024UncategorizedADC Bioanalysisbioadc

The emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules,Read More…

18Mar/24

How to Screen an ADC Payload?

March 18, 2024ReviewADC payloadbioadc

Introduction of the Camptothecin Derivative Payload Camptothecin was first isolated from camptothecin stems in 1966 by Wall et al., mainly in the form of topological isomerase (topoI). In order to inhibit theRead More…

18Mar/24

Several Ways to Sort Out Sulfhydryl-Conjugated ADCs

March 18, 2024ReviewADCs, Sulfhydryl-Conjugatedbioadc

The popularity of sulfhydryl groups in ADC preparation can be traced back to three factors: (a) thiols are the most nucleophilic amino acid side-chain functional group (much more nucleophilic than amines); (b)Read More…

24Feb/24

A Review of Bispecific ADC

February 24, 2024ReviewBispecific ADC, conjugation strategy, MEDI4276, ZW49bioadc

Antibody-drug conjugates (ADCs) comprise an antibody, a linker, and a cytotoxic active payload. Compared to traditional chemotherapy, ADCs that target tumors are expected to mitigate systemic toxic effects, provide a wider therapeuticRead More…

29Jan/24

New Highlights of ADC Targeting Intracellular Antigens—TCRm-ADC

January 29, 2024Antibody-drug Conjugates Researchmmae, TCRm-ADCbioadc

Intracellular proteins can be degraded, processed, and presented on the cell surface in complex with MHC molecules (HLA), which can be specifically recognized by TCR (Figure 1). Antibodies that recognize pMHC likeRead More…

22Dec/23

Key Points of ADC Optimization Strategy

December 22, 2023ReviewADC linker, ADC Optimization, antibody-drug conjugatebioadc

Antigen Target Selection A major challenge in developing antibody-drug conjugates (ADCs) for cancer lies in the identification and validation of sufficient antigen targets for the monoclonal antibody component. Several factors need toRead More…